Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.

@article{VerhaarLangereis2006PhaseIS,
  title={Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.},
  author={Marlies J. Verhaar-Langereis and Abdullah Karakuş and M. Van Eijkeren and Emile E Voest and Els Witteveen},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2006},
  volume={16 1},
  pages={
          65-70
        }
}
The combination of liposomal doxorubicin and topotecan was evaluated in a phase II study in patients with platinum-resistant ovarian cancer. Twenty-seven patients received liposomal doxorubicin (30 mg/m(2)) infused at day 1, followed by topotecan (1 mg/m(2)) infusion daily for 5 days. Cycles were repeated every 21 days. This combination regimen showed an overall response rate of 28%. Median time to progression was 30 weeks, with a median overall survival of 40 weeks. Grade 3/4 neutropenia was… CONTINUE READING

Similar Papers

Loading similar papers…